These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1308 related articles for article (PubMed ID: 25517451)

  • 1. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ; Hu C; King TM; Chiu YL; Wang JH; Liu RS
    Cancer Biother Radiopharm; 2013; 28(6):479-87. PubMed ID: 23713869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma.
    Belhocine T; De Barsy C; Hustinx R; Willems-Foidart J
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1132-9. PubMed ID: 12192557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].
    Zhao TT; Li JG; Li YM
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):206-9. PubMed ID: 17649638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.
    Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):480-6. PubMed ID: 17089122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy.
    Veit-Haibach P; Antoch G; Beyer T; Stergar H; Schleucher R; Hauth EA; Bockisch A
    Br J Radiol; 2007 Jul; 80(955):508-15. PubMed ID: 17537758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
    Kubota K; Yokoyama J; Yamaguchi K; Ono S; Qureshy A; Itoh M; Fukuda H
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):590-5. PubMed ID: 14722678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
    Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
    Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?
    Zoller M; Kohlfuerst S; Igerc I; Kresnik E; Gallowitsch HJ; Gomez I; Lind P
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):487-95. PubMed ID: 17103166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
    Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
    J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.
    van der Hoeven JJ; Krak NC; Hoekstra OS; Comans EF; Boom RP; van Geldere D; Meijer S; van der Wall E; Buter J; Pinedo HM; Teule GJ; Lammertsma AA
    J Clin Oncol; 2004 Apr; 22(7):1253-9. PubMed ID: 15051773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of positron emission tomography in the follow-up for breast cancer.
    Siggelkow W; Zimny M; Faridi A; Petzold K; Buell U; Rath W
    Anticancer Res; 2003; 23(2C):1859-67. PubMed ID: 12820470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantages and limitations of FDG PET in the follow-up of breast cancer.
    Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.